News >

Expert Discusses Treatment Advances in ALK-Positive NSCLC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 09, 2018

Erminia Massarelli, MD, PhD

Erminia Massarelli, MD, PhD
The November 2017 FDA approval of the ALK inhibitor alectinib (Alecensa) for the frontline treatment of patients with ALK-positive non–small cell lung cancer (NSCLC) quickly changed the standard of care. But ongoing research suggests that other ALK inhibitors are also poised to significantly impact this patient population.

-positive NSCLC based on recent regulatory decisions and what additional advancements are expected in the year ahead.

OncLive: Please provide an overview of your presentation on targeted therapies for ALK-positive NSCLC.

Massarelli: ALK-mutated NSCLC [makes up a small percentage] of all NSCLCs, and they are presented in a very selected group. They are usually associated with a never smoking history and a young patient population, and are generally diagnosed at metastatic stage. The treatment of [patients with] ALK-translocated lung cancer has been completely changed by our ability [to develop] ALK inhibitors. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung CancersNov 30, 20190.5
Publication Bottom Border
Border Publication